Durex licenses VivaGel
This article was originally published in The Tan Sheet
SSL International, the manufacturer of Durex brand condoms, signs a licensing agreement with Starpharma Holdings for marketing rights to a condomcoated with Starpharma's VivaGel, a vaginal microbicide gel under development for the prevention of sexually transmitted infections, including genital herpes and HIV infection, the firms announce Sept. 9. The deal secures SSL the rights to market a VivaGel coated condom in most markets, including Europe and the U.S., and Starpharma estimates it will receive more than $100 million from SSL for royalties on sales, further milestone payments and developmental support, Melbourne, Australia-based Starpharma says. The firm also continues to develop VivaGel as an applicator-delivered vaginal microbicide for women to protect against STIs
You may also be interested in...
A lack of regulatory harmonization for dietary supplements in Asia is a big challenge facing companies operating in the region, according to experts from the Asia Regulatory Professionals Association. The ARPA is looking to start a conversation on the issue which the association hopes will lead to regulatory change.
The Chinese Society of Clinical Oncology (CSCO) annual meeting, against the background of the global pandemic, has one clear message that local researchers and players are pressing ahead to take a leadership role in cutting-edge cancer research globally.
Company is confident that data readout from pivotal trial could be ready before the end of 2020.